Toulouse-based GTP Bioways has partnered with French biotech LinKinVax to develop a second-generation vaccine against Kovit-19. Messenger RNA is different from the vaccine in that it targets the area most susceptible to mutations to achieve a lasting effect. The first clinical trials are scheduled for 2023.
To live with Covit-19, the World Health Organization (WHO) is pushing for the development of second-generation vaccines that are long and effective in combating SARS-Cov 2 mutations. One of these solutions is Toulouse by GDP Bioways. The young company, formed in 2019, has partnered with the LinKinVax operating system to develop and manufacture the new Kovit-19 vaccine. The first clinical trials are expected next year.
Developed in November 2020, LinKinVax is based on the work of the Vaccine Research Institute (VRI), developed by the French National Agency for AIDS Research to accelerate the development of vaccines against HIV. “LinKinVax’s business is to provide innovative answers in the field of vaccination”, says Andre-Jack Aberton-Herv, co-founder and co-founder of LinKinVax, Pr Yves Lévy, Immunologist, Director of VRI and former Chairman of Inserm.
Long-term memory effect, easily distributed vaccine
For this vaccine, there is no question of messenger RNA. “Our vaccine is protein. A monoclonal antibody targets dendritic cells, the drones of the immune system. Like the authors, they teach how these cells respond to the immune system. Our technology will bring information to the recipient so that these authors will save time and performance and initiate a long lasting memory effect. We did not target the spike protein area, but the area less sensitive to viral mutations. Another advantage of the protein vaccine is that it is easy to prepare and distribute (preserved in a regular refrigerator or in frozen-dried form), “says Andre-Jack Aberton-Herv, who is pleased to be able to agree with a French subcontractor to manufacture medical packages.
GDP biowase works on the nasal vaccine
GTP Bioways has four bases, including a head office, a nano unit and a technology division in Toulouse and a site near Geneva (in partnership with the Farewa Group) for the production of antibodies. It employs 100 people with an income of 20 million euros a year and is already involved in developing the Nazi vaccine against Govt-19. “Our job is to create processes and produce them in the pharmaceutical environment. This is what we are going to do with the innovation that LinKinVax has come up with. The terminal bottles will be manufactured in Toulouse.
Edward Langley is a contributor to Nintendo-power.com, covering a wide range of topics including news, business, technology, entertainment, lifestyle and current affairs. He focuses on delivering clear, balanced and accessible reporting that helps readers stay informed about important developments and emerging trends. With an emphasis on accuracy, relevance and useful insights, Edward aims to provide engaging stories and practical information that matter to audiences in the UK and beyond.